Lipid-induced modulation of protective signalling pathways in cardiovascular disease: The role of high density lipoproteins

Current Signal Transduction Therapy

Volumn 7, Issue 2, 2012, Pages 96-103

  James, Richard W ^a   Frias, Miguel A ^a   Lecour, Sandrine ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Apolipoprotein AI; Cardiomyocyte; Endothelium; HDL; Ischemia reperfusion injury; SAFE pathway; Sphingosine 1 phosphate

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SCAVENGER RECEPTOR BI; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TORCETRAPIB; VASCULOTROPIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DRUG FATALITY; DRUG WITHDRAWAL; ENDOTHELIUM CELL; HEART MUSCLE CELL; HUMAN; HYPERTENSION; LIPOPROTEIN SYNTHESIS; MOLECULAR PATHOLOGY; NONHUMAN; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION;

EID: 84861941309     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436212800376627     Document Type: Review

References (64)

1. Herz J, Chen Y, Masiulis I, Zhou L. Expanding functions of lipoprotein receptors. J Lipid Res 2009; 50 Suppl: S287-92.
2. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121: 1-12. (Pubitemid 26072699)
3. Clerk A, Cullingford TE, Fuller SJ, et al. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol 2007; 212: 311-22. (Pubitemid 47025620)
4. Frias MA, Lang U, Gerber-Wicht C, James RW. Native and reconstituted HDL protect cardiomyocytes from doxorubicininduced apoptosis. Cardiovasc Res 2010; 85:118-26.
5. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9. (Pubitemid 23132154)
6. Norata GD, Catapano AL. Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vasc Health Risk Manage 2005; 1: 119-29.
7. Chatterjee A, Black SM, Catravas JD. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul Pharmacol 2008; 49: 134-40.
8. Kuvin JT, Patel AR, Sidhu M, et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Cardiol 2003; 92: 275-9. (Pubitemid 36897708)
9. Nofer JR, van der Giet M, Tölle M, et al. HDL induces NOdependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113: 569-81. (Pubitemid 38542506)
10. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001; 7: 853-7. (Pubitemid 32691642)
11. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107: 2944-8. (Pubitemid 36736637)
12. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105: 1399-402. (Pubitemid 34263266)
13. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. HDL-induced eNOS activation is mediated by Akt and MAP kinases. J Biol Chem 2003; 278: 9142-9.
14. Dudzinski DM, Igarashi J, Greif D, Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 2006; 46: 235-76. (Pubitemid 43271190)
15. Saddar S, Mineo C, Shaul PW. Signaling by the high-affinity HDL receptor scavenger receptor B type I. Arterioscler Thromb Vasc Biol 2010; 30: 144-50.
16. Kimura T, Tomura H, Sato K, et al. Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells. J Biol Chem 2010; 285: 4387-97.
17. Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE, Kingwell BA. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA 2004; 101: 6999-7004. (Pubitemid 38596432)
18. Levine YC, Li GK, Michel T. Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK→ Rac1→ Akt→ endothelial nitric-oxide synthase pathway. J Biol Chem 2007; 282: 20351-64. (Pubitemid 47100039)
19. Mineo C, Shaul PW. Role of high-density lipoprotein and scavenger receptor B type I in the promotion of endothelial repair. Trends Cardiovasc Med 2007; 17: 156-61. (Pubitemid 46898843)
20. Assanasen C, Mineo C, Seetharam D, et al. Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J Clin Invest 2005; 115: 969-77. (Pubitemid 40489401)
21. Kimura T, Sato K, Malchinkhuu E, et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 2003; 23: 1283-8. (Pubitemid 36871285)
22. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95. (Pubitemid 30208155)
23. Kirton JP, Xu Q. Endothelial precursors in vascular repair. Microvasc Res 2010; 79: 193-9.
24. Murugesan G, Sa G, Fox PL. High density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor. Circ Res 1994; 74: 1149-56. (Pubitemid 24176910)
25. Tauber JP, Cheng J, Gospodarowicz D. Effect of high and low density lipoproteins on proliferation of cultured bovine vascular endothelial cells. J Clin Invest 1980; 66: 696-708. (Pubitemid 10060938)
26. Seetharam D, Mineo C, Gormley AK, et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res 2006; 98: 63-72. (Pubitemid 43970204)
27. von Eckardstein A, Rohrer L. Transendothelial lipoprotein transport and regulation of endothelial permeability and integrity by lipoproteins. Curr Opin Lipidol 2009; 20: 197-205.
28. Sumi M, Sata M, Miura S, et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27: 813-8. (Pubitemid 46606711)
29. Tso C, Martinic G, Fan WH, et al. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 2006; 26: 1144-9. (Pubitemid 43732125)
30. Feng Y, Jacobs F, Van Craeyveld E, et al. Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 278-83. (Pubitemid 351161200)
31. Petoumenos V, Nickenig G, Werner N. High density lipoprotein exerts vasculoprotection via endothelial progenitor cells. J Cell Mol Med 2009; 13: 4623-35.
32. Rossi F, Bertone C, Montanile F, et al. HDL cholesterol is a strong determinant of endothelial progenitor cells in hypercholesterolemic subjects. Microvasc Res 2010; 80: 274-9.
33. van Oostrom O, Nieuwdorp M, Westerweel PE, et al. Reconstituted HDL increases circulating endothelial progenitor cells in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2007; 27: 1864-5. (Pubitemid 47207184)
34. Pearson JD. Endothelial progenitor cells-an evolving story. Microvasc Res 2010; 79: 162-8.
35. Feng Y, van Eck M, Van Craeyveld E, et al. Critical role of scavenger receptor-BI-expressing bone marrow-derived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer. Blood 2009; 113: 755-64.
36. Zhang Q, Yin H, Liu P, Zhang H, M. S. Essential role of HDL on endothelial progenitor cell proliferation with PI3K/Akt/cyclin D1 as the signal pathway. Exp Biol Med 2010; 235: 1082-92.
37. Walter DH, Rochwalsky U, Reinhold J, et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol 2007; 27: 275-82. (Pubitemid 46143040)
38. Mochizuki S, Okumura M, Tanaka F, et al. Ischemia-reperfusion arrhythmias and lipids: effect of human high-and low-density lipoproteins on reperfusion arrhythmias. Cardiovasc Drugs Ther 1991; Suppl 2: 269-76.
39. Calabresi L, Rossoni G, Gomaraschi M, et al. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 2003; 92: 330-7. (Pubitemid 36258556)
40. Marchesi M, Booth EA, Rossoni G, et al. Apolipoprotein AIMilano/ POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart. Atherosclerosis 2008; 197: 572-8. (Pubitemid 351417901)
41. Theilmeier G, Schmidt C, Hermann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006; 114: 1403-9. (Pubitemid 44454560)
42. Frias MA, James RW, Gerber-Wicht C, Lang U. Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate. Cardiovasc Res 2009; 82: 313-23.
43. Tao R, Hoover HE, Honbo N, et al. High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxiareoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol 2010; 298: H1022-8.
44. Hausenloy DH, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006; 70: 240-53.
45. Means CK, Xiao CY, Li Z, et al. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007; 292: H944-51.
46. Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 2009; 82: 193-200.
47. Means CK, Miyamoto S, Chun J, Brown JH. S1P1 receptor localization confers selectivity for Gi-mediated cAMP and contractile responses. J Biol Chem 2008; 283: 11954-63.
48. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J Mol Cell Cardiol 2009; 47: 32-40
49. Lecour S, Suleman N, Deuchar G, et al. Pharmacological preconditioning with TNF activates STAT-3 at reperfusion without involving classic prosurvival kinases (Akt and Erk). Circulation 2005; 112: 3911-8.
50. Suleman N, Somers S, Smith R, Opie LH, Lecour SC. Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 2008; 79: 127-33 (Pubitemid 351881934)
51. Babitt J, Trigatti B, Rigotti A, et al. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is Nglycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 1997; 272: 13242-9. (Pubitemid 27216752)
52. Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 2000; 352: 809-15. (Pubitemid 32015038)
53. Sattler KJ, Elbasan S, Keul P, et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 2010; 105: 821-32.
54. Kontush A, Therond P, Zerrad A, et al. Preferential sphingosine-1- phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007; 27: 1843-9. (Pubitemid 47207181)
55. Hausenloy DJ. Signalling pathways in ischaemic postconditioning. Thromb Haemost 2009; 101: 626-34.
56. Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in cardioprotection. J Cardiovasc Pharmacol 2009; 53: 189-97.
57. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009; 82: 201-11.
58. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8. (Pubitemid 29362514)
59. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22 (Pubitemid 350146106)
60. Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol 2009; 104(10 Suppl): 10E-5E.
61. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-300. (Pubitemid 37430562)
62. Tardif JC, Grégoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297: 1675-82. (Pubitemid 46631626)
63. Shaw JA, Bobil A, Murphy A, et al. Infusion of reconstituted highdensity lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008; 103: 1084-91.
64. Honda O, Sugiyama S, Kugiyama K, et al. Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. J Am Coll Cardiol 2004; 43: 1177-84. (Pubitemid 38452593)